Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX
Lexicon Pharmaceuticals — Q4 2024 Earnings Presentation
21 slides from Lexicon Pharmaceuticals's earnings presentation, Mar 6, 2025
Slide 1: Fourth Quarter and Full Year 2024 Earnings Presentation
Fourth Quarter and Full Year 2024 Earnings Presentation March 2025 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as pr
Slide 3: Business Overview
Business Overview Mike Exton, PhD Director and Chief Executive Officer 3
Slide 4: 2024: Repositioned to focus on advancing strong R&D pipeline
Company Overview 2024: Repositioned to focus on advancing strong R&D pipeline Refocused resources where Lexicon has potential to Lead to Succeed as a clinical-development focused company Accelerated topline data readout of PROGRESS, Phase 2b dose optimization study of pilavapadin in DPNP to Q1 2025
Slide 5: PROGRESS Phase 2b: LS Mean Change from Baseline at Week 8
Pilavapadin PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in DPNP identified 10 mg dose as most clinically meaningful pilavapadin pilavapadin pilavapadin Placebo 10 mg 20 mg/10 mg* 20 mg 0 LS Mean Change from Baseline at Week 8 -1 -1.31 -1.38 -1.74 -1.70 -2 p<0.001 for all groups vs Baseli
Slide 6: PROGRESS post-hoc analysis supports 10 mg for Phase 3
Pilavapadin PROGRESS post-hoc analysis reaffirms 10 mg as most appropriate to advance into Phase 3 clinical development Efficacy of pooled, 10 mg dosing arms (post-hoc) Key Findings 0.0 LS Mean Change from Baseline -0.5 • 10 mg dose demonstrated early and sustained separation from -1.0 placebo (slid
Slide 7: PROGRESS 10 mg dose had placebo-like study completion rate
PROGRESS 10 mg dose had placebo-like study completion rate Placebo 10 mg 20 mg/10 mg 20 mg Total (N = 124) (N = 123) (N = 124) (N =125) (N = 496)* n (%) n (%) n (%) n (%) n (%) Number of patients completed 109 ( 87.9) 108 ( 87.8) 102 ( 82.3) 96 ( 76.8) 415 ( 83.7) Number of patients discontinued 14
Slide 8: A clear need and opportunity in the DPNP treatment landscape
Pilavapadin A clear need and opportunity in the DPNP treatment landscape for new treatments Sizable Market Opportunity for DPNP High Unmet Need ~9 Low Alternatives 60% Million Satisfaction to Pain Act U.S. patients with of patients have with current physicians progressive DPNP tried multiple treatme
Slide 9: LX9851 potential to address unmet needs in obesity
LX9851 Based on pre-clinical studies, LX9851 has the potential to address unmet needs in obesity and related cardiometabolic disorders LX9851 First in class, potent and selective orally bioavailable, investigational small molecule ACSL5 inhibitor Biology-based Mechanism to Address Obesity Potential
Slide 10: Further differentiating sotagliflozin among SGLT class
Sotagliflozin Focused on further differentiating sotagliflozin among SGLT class and maintaining a scientific presence in CV 2025 Focus: Bridging strategy to potential HCM indication INPEFA remains available on the market with continued commitment to maintain awareness and provide tools to support pa
Slide 11: The Lancet highlights unique efficacy benefits of sotagliflozin
Sotagliflozin The Lancet Diabetes & Endocrinology highlights unique efficacy benefits of sotagliflozin Cumulative incidence of total MACE by treatment group 12 11.6 Placebo Sotagliflozin 10.0 9 • Reduced major adverse cardiovascular events Events (per 100 patients) (MACE), MI and stroke among patien
Slide 12: Financial Overview
Financial Overview Scott Coiante Chief Financial Officer 12
Slide 13: Q4 and FY 2024 Financial Summary
Financials Q4 and FY 2024 Financial Summary Note: $ in Millions except per share amounts Q4 2024 Q4 2023 FY 2024 FY 2023 As of December As of December 31, 2024 31, 2023 Total revenues $26.6 $.70 $31.1 $1.2 Cash, cash equivalents R&D $26.7 $14.8 $84.5 $58.9 and short-term $238.0 $170.0 investments SG
Slide 14: 2025 guidance reflects significantly lower operating expenses
Financials 2025 guidance reflects significantly lower operating expenses • Announced strategic restructuring to reduce operating costs • Reduction of number of employees by approximately 70 percent 2H 2024 Key • Elimination of promotional activities for INPEFA Financial Highlights • Licensing agreem
Slide 15: Summary
Summary Mike Exton, PhD Director and Chief Executive Officer 15
Slide 16: Significant number of planned catalysts through 2025
Conclusion Significant number of planned catalysts through 2025 Pipeline Indication Planned Catalyst 2025 • Full PROGRESS data anticipated in Q2 • Diabetic Peripheral Neuropathic • End of Phase 2 meeting planned in Q3 Pilavapadin Pain • Data at upcoming medical meetings, potentially including: ADA,
Slide 17: Q&A
Q&A Mike Exton, PhD Craig Granowitz, MD, PhD Scott Coiante Director and Chief Senior Vice President and Chief Chief Financial Officer Executive Officer Medical Officer 17
Slide 18: Thank You
Thank You pharmaceuticals
Slide 19: Appendix
Appendix pharmaceuticals
Slide 20: 10 mg demonstrated an early, sustained separation from placebo
10 mg demonstrated an early, sustained separation from placebo RELIEF-DPN-1 Phase 2a PROGRESS Phase 2b 0.0 0.0 0.0 Mean Change from Baseline -0.5 -0.5 LS Mean Change from Baseline -0.5 LS Mean Change from Baseline -1.0 -1.0 -1.0 -1.5 -1.5 -1.5 Placebo LX9211 10 mg Placebo LX9211 100 mg/10 mg Placebo
Slide 21: PROGRESS 10 mg dose was well-tolerated with few discontinuations
PROGRESS 10 mg dose was well-tolerated with few treatment discontinuations Placebo 10 mg 20 mg/10 mg 20 mg Total (N = 124) (N = 122) (N = 122) (N =124) (N = 492)* n (%) n (%) n (%) n (%) n (%) Subjects who discontinued 2 (1.6) 9 (7.4) 14 (11.5) 22 (17.7) 47 (9.6) who had a TEAE Dizziness 0 3 (2.5) 1
Lexicon Pharmaceuticals — Q4 2024 Earnings Presentation on 6ix